Company Overview and News

26
Community Health Divests Unit to Focus on Core Business

2018-10-04 zacks - 1
Community Health Systems, Inc. (CYH - Free Report) recently announced that it has completed its pending divestiture of the 238-bed AllianceHealth Deaconess hospital in Oklahoma City, OK and its related businesses to a unit of INTEGRIS Health. The sale also consists of physician clinic operations and outpatient services. The effective date of the transaction is Oct 1, 2018. The company’s affiliates continue to operate seven hospitals in Oklahoma.
LMT CYH MOH RNVAZ RNVA WCG CYHHZ ANTM UTX RNVAW

27
Implied Volatility Surging for Community Health (CYH) Stock Options

2018-10-04 zacks
Investors in Community Health Systems, Inc. (CYH - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 15, 2019 $4.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
CYH CSBR CYHHZ

25
Community Health's (CYH) Ratings Downgraded, Outlook Stable

2018-09-28 zacks
Credit rating giant Moody's Investors Service ("Moody's") recently downgraded the Corporate Family Rating (CFR) of Community Health Systems, Inc. (CYH - Free Report) from Caa2 to Caa3 and the Probability of Default Rating from Caa2-PD to Caa3-PD. The agency has further downgraded the first lien senior secured debt to Caa1 from B3, the junior lien debt to Ca from Caa3, the unsecured debt to C from Ca and the Speculative Grade Liquidity Rating to SGL-4 from SGL-3.
CYH MOH CBT WCG CYHHZ ANTM RPM

27
Community Health's (CYH) Subsidiary to Clear Fraud Charges

2018-09-27 zacks
Community Health Systems, Inc. (CYH - Free Report) subsidiary Health Management Associates (HMA) will pay more than $260 million to settle whistleblower lawsuits alleging wide-ranging misconduct in emergency rooms. This includes $62.5 million to settle allegations that HMA forced physicians to make unnecessary admissions to its hospitals.
CYH NBL LPNT MEDP CYHHZ

30
CYH / Community Health Systems, Inc. FORM 8-K (Current Report)

2018-09-26 sec.gov - 5
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CYH

27
Community Health unit to pay US$260 million to resolve US fraud probe

2018-09-25 channelnewsasia - 2
REUTERS: A hospital operator now owned by Community Health Systems Inc will pay more than US$260 million to resolve claims it defrauded government health care programs and paid doctors kickbacks for patient referrals, the U.S. Justice Department said on Tuesday.
CYH CYHHZ

25
Community Health unit to pay $260 mln to resolve U.S. fraud probe

2018-09-25 reuters
(Reuters) - A hospital operator now owned by Community Health Systems Inc will pay more than $260 million to resolve claims it defrauded government health care programs and paid doctors kickbacks for patient referrals, the U.S. Justice Department said on Tuesday.
CYH CYHHZ

25
HYG And U.S. High-Yield Market Outlook: Week Ending September 16, 2018

2018-09-19 seekingalpha
HYG was up 74 bps on the last week compared to significant value loss in a week before.
CYH

31
Will Hurricane Florence Hurt LifePoint's Patient Volumes?

2018-09-13 zacks
LifePoint Health Inc. (LPNT - Free Report) has high exposure to Hurricane Florence, with 30% of its beds in North and South Carolina, which is within the forecast path of the storm, as per analysts as pointed out in CNBC news. This makes the stock vulnerable to earnings miss in the third quarter. Other companies to face the wrath include Community Health Systems, Inc. (CYH - Free Report) , HCA Healthcare, Inc.
CYH LPNT CYHHZ ENPH OXY THC

25
Community Health Systems (CYH) Presents at Baird's Global Healthcare Conference - Slideshow

2018-09-07 seekingalpha
The following slide deck was published by Community Health Systems, Inc. in conjunction with this event.
CYH CYHHZ

25
Is the Options Market Predicting a Spike in Community Health (CYH) Stock?

2018-09-05 zacks
Investors in Community Health Systems, Inc. (CYH - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 15, 2019 $2.00 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
CYH HDS CYHHZ

112
8 Cheap Stocks That Cost Less Than $10

2018-08-30 investorplace - 2
Cheap stocks are never “sure things.” There are many cheaply traded companies, even penny stocks, under $10 right now that deserve to be there and will only get cheaper.
BAC RBS CYH BLK AGFS AMZN AGFSW EVRI AVP CYHHZ HLIT BKCC

25
RENNOVA HEALTH REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS

2018-08-14 globenewswire
WEST PALM BEACH, Fla, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Rennova Health, Inc. (OTC: RNVA), (OTC: RNVAW), (“Rennova” or the “Company”) a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers that acquired its second rural hospital in Tennessee on June 1, 2018, reports financial results for the three and six months ended June 30, 2018 and provides a business update.
CYH RNVAZ RNVA CYHHZ RNVAW

32
3 Ideas For August 2018: P/E Vs. EV/EBITDA

2018-08-01 seekingalpha - 2
People who use EBITDA are either trying to con you or they're conning themselves." - Warren Buffett
CYH DHI QHC CYHHZ QCOM

26
CYH / Community Health Systems, Inc. FORM S-8

2018-07-31 sec.gov - 1
Form S-8 As filed with the Securities and Exchange Commission on July 31, 2018 Registration No. 333-______
CYH

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to CYH / Community Health Systems, Inc. on message board site Silicon Investor.

CYH.Ase CYH.Ase CYH.Ase
CUSIP: 203668108